NFCR is well-recognized by the scientific community for the unique role we play in accelerating cancer research. There are six primary advantages of our funding over other sources:

• Seed Funding—NFCR provides seed funding for innovative research that is difficult, if not impossible, to obtain from other sources. NFCR has been the incubator for many of the most important discoveries in cancer research for nearly four decades.
• Flexibility—NFCR’s funding is more flexible than other charities, allowing scientists to pursue promising and unanticipated discoveries during the course of their research. This flexibility accelerates the pace at which treatment options for cancer patients can move from bench to the bedside.
• Collaboration—NFCR actively facilitates and fosters collaboration among scientists and serves as a catalyst to accelerate life-saving research.
• Global Reach—NFCR is a bridge connecting scientist in their laboratories around the world in the pursuit of a cure for cancer. NFCR overcomes barriers to progress, bringing the best ideas and the best minds together, regardless of location.
• Multiple Perspectives—NFCR’s multi-disciplinary approach encourages scientists from different fields to join forces to accelerate the pace of cancer research.
• Long-Term Vision—NFCR demonstrates a long-term vision and commitment to cancer research. As a leading cancer charity, NFCR can provide cutting-edge ideas with resources and time to develop.

NFCR Research Discovery Centers

Each of the Centers is directed by a highly accomplished cancer research leader. Those Centers form an international network that constitutes NFCR's "Laboratory Without Walls" - promoting the sharing of ideas and information across research institutions and engaging top research minds from a wide range of scientifi c disciplines.

	NFCR Center for Therapeutic Antibody Engineering Dana - Farber Institute/ Harvard University Boston, Massachusetts		NFCR Center for Targeted Cancer Therapies Translational Genomics Research Institute Phoenix, Arizona
	NFCR Center for Molecular Imaging Case Western Reserve University Cleveland, Ohio		NFCR Center for Metastasis Research University of Kansas/Penn State University/University of Chicago Westwood, Kansas
	Joint Tissue Banking Facility Tianjin Medical University Cancer Institute and Hospital Tianjin, China

NFCR Research Fellows

This program is currently providing long-term and flexible funding to the distinguished and well-established scientists who are leaders in their respective research fields with close connections to research hospitals. This unique funding approach enables NFCR Fellows to perform innovative research in the laboratories and collaborate with clinicians in the hospitals to convert the potential life-saving discoveries into actual applications to benefit cancer patients.

	Webster Cavenee, Ph.D. Ludwig Institute for Cancer Research San Diego, California		Yung-Chi Cheng, Ph.D. Yale University School of Medicine New Haven, Connecticut
	Curt I. Civin, M.D. University of Maryland School of Medicine Baltimore, Maryland		Stanley N. Cohen, M.D. Stanford University School of Medicine Stanford, California
	Harold F. Dvorak, M.D. Beth Israel Deaconess Medical Center Boston, Massachusetts		Waun Ki Hong, M.D. M.D. Anderson Cancer Center Houston, Texas
	Susan Band Horwitz, Ph.D. Albert Einstein College of Medicine Bronx, New York		Alan C. Sartorelli, Ph.D. Yale University New Haven, Connecticut
	Paul Schimmel, Ph.D. The Scripps Research Institute La Jolla, California		Helmut Sies, M.D. Heinrich-Heine-Universitat Dusseldorf, Germany

NFCR Project Directors

This program is designed to encourage outstanding scientists to explore previously uncharted territories in search of the hidden causes of cancer. This research approach cultivates healthy academic competitions and provides scientists a precious opportunity to validate their most innovative ideas.

	Robert Bast, Jr., M.D. M.D. Anderson Cancer Center Houston, Texas		Rakesh K. Jain, Ph.D. Massachusetts General Hospital Boston, Massachusetts
	Esther H. Chang, Ph.D. Georgetown University Washington, DC		William Jorgensen, Ph.D. Yale University New Haven, CT
	Laurence J. N. Cooper, M.D., Ph.D. M.D. Anderson Cancer Center Houston, Texas		Janos Ladik, Ph.D. Universitaet Erlangen-Nurnberg Erlangen, Germany
	Paul B. Fisher, M.Ph., Ph.D. VCU School of Medicine and the Massey Cancer Center Richmond, Virginia		Alanna Schepartz, Ph.D. Yale University New Haven, CT
	Daniel A. Haber, M.D., Ph.D. Massachusetts General Hospital Cancer Center Charleston, Massachusetts		Michael Sporn, M.D. Dartmouth Medical School Hanover, New Hampshire
	Kathryn Horwitz, Ph.D. University of Colorado		Wei Zhang, Ph.D. M.D. Anderson Cancer Center Houston, Texas

Success Stories Showcase

	Cutting off a Tumor's Blood Supply: The Life-Saving Drug AvastinTM		The Power of Personal Computers to Fight Cancer
	New Technology that is 14,000 Times Faster than other Technologies		New Drug for Leukemia, Brain Tumors, and Small Cell Lung Cancer

Click here to view more success stories.

NFCR Progress Reports

• Selected Previously Funded Scientists
• Selected Previously Funded Programs